Inflammatory Pain - Pipeline Insight, 2024

This “Inflammatory Pain - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Inflammatory Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Inflammatory Pain Understanding

Inflammatory Pain: Overview

Inflammatory pain is associated with inflammatory response due to harmful stimuli. The damaged tissue because of an external stimuli is responsible for the activation of inflammatory mediators which leads to potentiation of pain. The inflammatory process plays a protective role by activating the immune system but it can also exacerbate painful symptoms. Symptoms can include redness, joint pain, fever, swollen area that might be warm to touch.

Inflammatory Pain - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammatory Pain pipeline landscape is provided which includes the disease overview and Inflammatory Pain treatment guidelines. The assessment part of the report embraces, in depth Inflammatory Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inflammatory Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Inflammatory Pain R&D. The therapies under development are focused on novel approaches to treat/improve Inflammatory Pain.

Inflammatory Pain Emerging Drugs Chapters

This segment of the Inflammatory Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Inflammatory Pain Emerging Drugs

CNTX 6970: Centrexion TherapeuticsCentrexion’s lead drug candidate, CNTX 6970 is an orally administered small molecule in development for the treatment of inflammatory pain. The drug is a CCR 2 receptor antagonist with dual effects. It inhibits the immune cells from releasing potent cytokine CCL2 and further stop it from stimulating pain fibers and from sending signals for pain.

Inflammatory Pain: Therapeutic Assessment

This segment of the report provides insights about the different Inflammatory Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Inflammatory Pain

There are approx. 3+ key companies which are developing the therapies for Inflammatory Pain. The companies which have their Inflammatory Pain drug candidates in the most advanced stage, i.e. phase II include, Centrexion Therapeutics.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Inflammatory Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Topical
• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inflammatory Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammatory Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammatory Pain drugs.

Inflammatory Pain Report Insights

• Inflammatory Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Inflammatory Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Inflammatory Pain drugs?
• How many Inflammatory Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammatory Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inflammatory Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Inflammatory Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Centrexion Therapeutics

Key Products

• CNTX 6970

This product will be delivered within 2 business days.